$ABCL

Montalbano John S. purchased $110K of ABCL

Montalbano John S. purchased 10,000 shares of AbCellera Biologics Inc. (ABCL) at $11.03 ($0.11M total) on 2026-08-18.

Original reporting
SEC EDGAR · Montalbano John S.
Published Aug 18, 2026, 6:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 6:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABCL
Bullish
medium confidence
Mentioned
$ABCL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABCLBullishLow
01

Why it matters

This is a disclosed open-market purchase by a director, which may modestly support sentiment but does not introduce new company fundamentals in the text.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no additional operational or financial catalyst provided.

03

What to watch

The filing lacks context on whether the purchase is opportunistic versus planned, and it provides no linkage to upcoming catalysts (earnings, trial readouts, or financing).

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for AbCellera Biologics Inc. (ABCL).

Company-level read

Ticker impact

$ABCLBullishMedium confidence
Context

Director Montalbano John S. filed a Form 4 open-market purchase of 10,000 ABCL shares at $11.03 on 2026-08-18.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the article provides no accompanying company-specific operational update, and the transaction is not described as part of a 10b5-1 plan.

Market effects

Minimal; this is a single insider transaction with no sector-wide regulatory or clinical signal.

None indicated.

None indicated.

Counterpoint

Insider buying can be routine diversification or personal liquidity planning, and without a 10b5-1 plan it still does not guarantee future performance.

Key entities

  • AbCellera Biologics Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Montalbano John S.

    Director who purchased 10,000 ABCL shares at $11.03 on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

$IOVAMedAI 8/10

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

Iovance (IOVA) surged 31% to a 2-year high after raising its 2026 revenue outlook to $410M-$420M, exceeding consensus. AbCellera (ABCL) gained 6% with JPMorgan initiating coverage with an 'Overweight' rating and $17 target. CrowdStrike (CRWD) rose 1% after announcing plans to integrate with OpenAI's marketplace. Retail sentiment improved for IOVA and ABCL but remained bearish for CRWD.

$FICOMed

Premarket movers: FICO sinks while Summit, AAR and CarMax rise

U.S. stock futures were flat on Tuesday. Summit Therapeutics (SUM) rose 17.1% after AstraZeneca's $2B investment. Fair Isaac (FICO) fell 15% due to FHFA mortgage pricing changes. CarMax (KMX) gained 3.7% on strong Q2 earnings. AAR Corp. (AIR) surged 6.9% after a $4B acquisition and earnings beat. Netflix (NFLX) rose 1.4% after a Deutsche Bank upgrade.

$ABCLHigh

Why is Abcellera Biologics stock climbing today?

Abcellera Biologics (ABCL) stock rose 2.1% pre-market after JPMorgan initiated coverage with an Overweight rating and $17 price target, citing confidence in its clinical-stage pipeline. The stock has gained over 400% in a year, driven by strong Phase 2 data for its menopause drug, ABCL635. Analysts broadly see upside from current levels, with a consensus price target above $14.23.

$ABCLMedAI 8/10

Goldman Sachs resumes AbCellera stock coverage with neutral rating

Goldman Sachs resumed coverage of AbCellera Biologics (NASDAQ:ABCL) with a Neutral rating and a $13.00 price target. The company reported Q2 revenue of $4.1M, missing estimates, but announced successful Phase 2 trial results for ABCL635, leading Truist to raise its price target to $30. AbCellera has a strong cash position and recently launched a $200M stock offering.

$ABCLHighAI 8/10

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera Biologics (ABCL) stock rose 121% in 3 months, outpacing its industry. The surge was driven by positive phase II data for ABCL635, a treatment for menopause symptoms, and new partnerships. The study met primary endpoints, showing significant reductions in hot flash frequency and severity. Additional data is expected in October. The company also reported strong financial stability and investor confidence.